Dianexin - Kowa
Alternative Names: Annexin A5 - Kowa; Annexin V - Kowa; Calphobindin; Caphobindin 1; Carfovindin; CPB I; KK 001; rCPB ILatest Information Update: 17 Sep 2014
Price :
$50 *
At a glance
- Originator Akita University; Kowa
- Class Anti-inflammatories; Anti-ischaemics; Anticoagulants; Antithrombotics; Antivirals; Biological peptides; Calcium binding proteins; Cardiovascular therapies; Eye disorder therapies; Recombinant fusion proteins
- Mechanism of Action Phosphatidylserine receptor modulators; Phospholipase A2 inhibitors; Urokinase-type plasminogen activator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Blood coagulation disorders
Most Recent Events
- 18 Feb 2005 Discontinued - Preclinical for Coagulation disorders in Japan (unspecified route)
- 14 Jan 2004 No development reported - Preclinical for Coagulation disorders in Japan (unspecified route)
- 19 Mar 2002 Calphobindin 1 is now called annexin V